Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 6/20 | 0.77 |
| ▸ | F12 | P00748 | 10/20 | 0.57 |
| ▸ | PIN1 | Q13526 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29932137 | 1.00 | CXCR4 (0.77) | CXCR4F12PIN1 | |
| SCHEMBL15987184 | 1.00 | CXCR4 (0.77) | CXCR4F12PIN1 | |
| SCHEMBL29466599 | 0.97 | CXCR4 (0.73) | CXCR4F12 | |
| SCHEMBL29370908 | 0.97 | CXCR4 (0.73) | CXCR4F12 | |
| SCHEMBL31692775 | 0.97 | CXCR4 (0.73) | CXCR4F12 | |
| SCHEMBL29466605 | 0.95 | CXCR4 (0.71) | CXCR4F12 | |
| SCHEMBL29836096 | 0.94 | CXCR4 (0.68) | CXCR4F12 | |
| SCHEMBL29932269 | 0.94 | CXCR4 (0.68) | CXCR4F12 | |
| SCHEMBL29932059 | 0.94 | CXCR4 (0.68) | CXCR4F12 | |
| SCHEMBL29932154 | 0.94 | CXCR4 (0.68) | CXCR4F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540172-B2 | Therapeutic nanoconjugates comprising Stefin A and uses thereof | UNIVERSITAT AUTONOMA DE BARCELONA (UAB) (ES) | 2026-02-03 | — | — | US | disclosed |
| US-20250288704-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München (DE) | 2025-09-18 | — | — | US | disclosed |
| US-20250243250-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | UNIV AUTÒNOMA DE BARCELONA UAB (ES) | 2025-07-31 | — | — | US | disclosed |
| CN-119661653-A | CXCR4 targeted diagnostic and therapeutic agents with reduced species selectivity | 慕尼黑工业大学 | 2025-03-21 | — | — | CN | disclosed |
| US-12202866-B2 | Therapeutic nanoconjugates and uses thereof | UNIVERSITAT AUTONOMA DE BARCELONA (UAB) (ES) | 2025-01-21 | — | — | US | disclosed |
| CN-112673015-B | CXCR4 targeted diagnostic and therapeutic agents with reduced species selectivity | 慕尼黑工业大学 | 2025-01-07 | — | — | CN | disclosed |
| US-12116592-B2 | Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs) | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| US-20240293587-A1 | CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY | Technische Universität München (DE) | 2024-09-05 | — | — | US | disclosed |
| EP-3849997-B1 | CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY | UNIV MUENCHEN TECH (DE) | 2024-05-01 | — | — | EP | disclosed |
| US-11944691-B2 | CXCR4-targeted diagnostic and therapeutic agents with reduced species selectivity | Technische Universität München (DE) | 2024-04-02 | — | — | US | disclosed |
| US-20230068834-A1 | SCAFFOLD PROTEINS AND THERAPEUTIC NANOCONJUGATES BASED ON NIDOGEN | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2023-03-02 | — | — | US | disclosed |
| US-11590198-B2 | Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells | UNIVERSITAT AUTONOMA DE BARCELONA (ES) | 2023-02-28 | — | — | US | disclosed |
| EP-4081538-A1 | SCAFFOLD PROTEINS AND THERAPEUTIC NANOCONJUGATES BASED ON NIDOGEN | Universitat Autònoma de Barcelona (ES) | 2022-11-02 | — | — | EP | disclosed |
| WO-2022171869-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-08-18 | — | — | WO | disclosed |
| EP-4043041-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-08-17 | — | — | EP | disclosed |
| US-11312940-B2 | Progenitor cells and methods for preparing and using the same | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220072084-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | UNIVERSITAT AUTONOMA DE BARCELONA (UAB) (ES) | 2022-03-10 | — | — | US | disclosed |
| US-20220056404-A1 | METHODS AND COMPOSITIONS FOR EX VIVO EXPANSION OF VERY SMALL EMBRYONIC-LIKE STEM CELLS (VSELS) | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220040339-A1 | CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY | Technische Universität München (DE) | 2022-02-10 | — | — | US | disclosed |
| US-20220041674-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS FOR CANCER | Technische Universität München (DE) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040339-A1 | CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY | CXCR4, CXCR3, ACKR3 | CXCR4 1/4885F12 3065/4885PIN1 3027/4885 |
| US-20220041674-A1 | THERAPEUTIC AND DIAGNOSTIC AGENTS FOR CANCER | CXCR4, CXCL12, CXCR3 | CXCR4 1/4885F12 3396/4885PIN1 3287/4885 |
| US-20240293587-A1 | CXCR4-TARGETED DIAGNOSTIC AND THERAPEUTIC AGENTS WITH REDUCED SPECIES SELECTIVITY | CXCR4, CXCR3, ACKR3 | CXCR4 1/4885F12 3065/4885PIN1 3027/4885 |
| US-20250288704-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | CXCR4, CXCR1, CXCR3 | CXCR4 1/4885F12 1784/4885PIN1 1341/4885 |
| US-11944691-B2 | CXCR4-targeted diagnostic and therapeutic agents with reduced species selectivity | CXCR4, CXCR3, ACKR3 | CXCR4 1/4885F12 3065/4885PIN1 3027/4885 |
| US-12540172-B2 | Therapeutic nanoconjugates comprising Stefin A and uses thereof | MYOF, MSTN, NGLY1 | CXCR4 3228/4885F12 1158/4885PIN1 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.